WallStSmart
REPL

Replimune Group Inc

NASDAQ: REPL · HEALTHCARE · BIOTECHNOLOGY

$5.41
+1.12% today

Updated 2026-07-29

Market cap
$858.76M
P/E ratio
P/S ratio
EPS (TTM)
$-3.63
Dividend yield
52W range
$2 – $13
Volume
5.4M

Replimune Group Inc (REPL) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2017201820192020202120222023202420252026
Revenue$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$122000.00$109000.00$148000.00$1.81M$4.14M$4.58M$2.45M$2.65M$3.50M
Gross profit$-122000.00$-109000.00$-148000.00$-1.81M$-4.14M$-4.58M$-2.45M$-2.65M$-3.50M
Gross margin
R&D$6.94M$13.52M$22.17M$38.76M$57.49M$80.64M$126.53M$174.96M$189.45M$221.18M
SG&A$2.71M$5.71M$8.77M$16.55M$23.20M$38.77M$50.55M$59.81M$72.18M$98.73M
Operating income$-9.65M$-19.23M$-30.95M$-56.20M$-82.76M$-121.48M$-177.08M$-234.77M$-261.63M$-319.92M
Operating margin
EBITDA$-8.08M$-16.85M$-30.69M$-52.58M$-76.48M$-114.41M$-171.72M$-227.77M$-253.92M$-302.30M
EBITDA margin
EBIT$-8.21M$-16.96M$-30.83M$-53.11M$-80.62M$-118.98M$-174.17M$-232.85M$-259.85M$-305.63M
Interest expense$0.00$0.00$0.00$1.92M$3.06M$2.22M$4.16M$6.66M$7.89M$8.86M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-7.70M$-19.70M$-30.83M$-52.63M$-80.87M$-118.04M$-174.28M$-215.79M$-247.30M$-313.94M
Net income growth (YoY)-155.7%-56.5%-70.7%-53.7%-46.0%-47.7%-23.8%-14.6%-26.9%
Profit margin

Frequently asked questions

How much free cash flow does REPL generate?

REPL produced $-284.57M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is REPL's balance sheet healthy?

REPL holds $209.02M in cash and equivalents against $83.31M in long-term debt, on $166.16M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.